Edition:
United States

DURECT Corp (DRRX.OQ)

DRRX.OQ on NASDAQ Stock Exchange Global Market

1.12USD
22 Feb 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.12
Open
$1.12
Day's High
$1.15
Day's Low
$1.10
Volume
38,177
Avg. Vol
184,874
52-wk High
$2.17
52-wk Low
$0.74

Chart for

About

Durect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY... (more)

Overall

Beta: 1.80
Market Cap(Mil.): $166.37
Shares Outstanding(Mil.): 148.55
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 189.80 16.52
EPS (TTM): -- -- --
ROI: -- -0.65 36.19
ROE: -- -3.21 17.38

BRIEF-Durect reports Q3 earnings per share of ‍$0.04​

* Durect Corporation announces third quarter 2017 financial results and provides corporate update

Nov 01 2017

BRIEF-Durect announces top-line results from the persist phase 3 trial of Posimir® did not meet primary efficacy endpoint

* Durect announces top-line results from the persist phase 3 trial of Posimir® (saber®-bupivacaine) did not meet primary efficacy endpoint

Oct 19 2017

BRIEF-Indivior says ‍durect, co sign $17.5 mln patent purchase deal

* DURECT AND INDIVIOR PLC SIGN A $17.5 MILLION PATENT PURCHASE AGREEMENT​

Oct 02 2017

BRIEF-Durect appoints Myriam Theeuwes as senior vice president of clinical development

* Durect appoints Dr. Myriam Theeuwes as senior vice president, clinical development Source text for Eikon: Further company coverage:

Sep 20 2017

Earnings vs. Estimates